Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Kissei Pharmaceutical Co ( (JP:4547) ).
Kissei Pharmaceutical has entered into a licensing agreement with Searchlight Pharma to develop and commercialize the GnRH antagonist ‘Linzagolix’ in Canada. This agreement allows Kissei to receive upfront, milestone, and royalty payments, while Searchlight will handle the product’s development and sales in Canada. Linzagolix, which targets uterine fibroids and endometriosis, is already launched in Europe and under development in Asia, showcasing Kissei’s strategic efforts to expand its global footprint and strengthen its position in the women’s health market.
The most recent analyst rating on (JP:4547) stock is a Buy with a Yen4943.00 price target. To see the full list of analyst forecasts on Kissei Pharmaceutical Co stock, see the JP:4547 Stock Forecast page.
More about Kissei Pharmaceutical Co
Kissei Pharmaceutical Co., Ltd. is a company focused on the research and development of new drugs, particularly in the field of women’s health. Their primary products include innovative pharmaceuticals aimed at treating conditions like uterine fibroids and endometriosis. The company collaborates with international partners to expand its market reach and contribute to global health.
Average Trading Volume: 79,040
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen174B
Learn more about 4547 stock on TipRanks’ Stock Analysis page.